Amgen, Inc. NASDAQ:AMGN yesterday declared the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, December 7, 2011.
About 98,062,630 shares of Amgen’s common stock were properly tendered and not properly withdrawn at or below the purchase price of $60 per share, including 30,827,827 shares that were tendered through notice of guaranteed delivery. The data is provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer.
AMGN is basically a Biotechnology industry company. The sales of company resulted $15.45 billion for last consecutive twelve months, and the company’s net income recorded $3.77 billion. The company’s growth of its sales (5-Year Annual Avg.) in recent quarter vs. year ago quarter recorded 3.90% which is below from Standard and Poor’s benchmark of 8.24%.
Company is on an optimistic track of growth as the pre-tax margin of Amgen, Inc. is 26.5% which is above the industry benchmark for pre-tax margin of -683.4% and above the Standard and Poor’s benchmark for pre-tax margin of 18.1%.
The stock price of company on December 08, 2011 increased 0.11% and settled to the closing price of $58.40. The overall volume in the last trading session was 41.56 million shares. Its fifty two week range was $47.66-$61.53. The total market capitalization remained $51.19 billion.
AMGN current stock price is moving above its 52 week low by 22.53% and moving below from 52 week high price by 5.09%. AMGN last month stock price volatility remained 1.64%. In its share capital AMGN has 876.54 million outstanding shares while company’s float is the same 875.47 million shares. Ownership of company is 82.09% institutional.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here